u/rania_marchand

I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

A symptom that begins the day after the shot and fades by day four tracks the exposure curve. One that appears at random in week 14 probably does not, and that is worth saying to a clinician rather than to us.

the weight numbers are secondary to what this is being developed for

fibre and water before you buy anything to fix it

Disagreeing with this one line: that symptom is not on the wait-and-see list and should not be posted as though it is.

the diabetes trials report different endpoints from the obesity ones

stepping every four weeks is a ceiling on speed, not a schedule you must hit

reflux at night, try not eating in the three hours before bed

holding a dose an extra month is a legitimate answer to bad tolerance

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

Hair shedding after significant weight loss is a telogen effect that follows the rate of loss. It is not specific to these compounds and it resolves.

keep the prescription and the receipt, both matter for claims

Adding the practical step — read your own country’s published criteria. They exist and they are definitive.

Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low. Risk rises with agents that act independently of glycaemia.

a lot of people plateau nicely at 10mg and never need 15

Small fix — the shedding follows the rate of weight loss, not the compound, and it is temporary.

the hepatic data is what makes this compound different from the others

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

A1c is a three-month average and it lags everything

Week 30 was the first time the scale moved after a five-week stall. I changed nothing in that window.

glycaemic control and weight are two different endpoints

Yes. Pack sizes differ enough that per-month price comparisons across borders need to be normalised before they mean anything.

Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.

Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.

This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.

Correction: that trial is the diabetes programme and the figure you quoted is its glycaemic endpoint, not a weight result.

Severe or persistent abdominal pain sits outside the pattern this board can usefully discuss. The honest answer there is that it needs someone who can examine you.

Cosigning the fibre and water answer. Unglamorous, free, and it fixed it for me inside a week.

this is a less-travelled board and the evidence base shows it

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

Nobody warned me about constipation and I would have liked the warning. It was not dangerous, it was just deeply unpleasant and completely unexpected.

How fast was the escalation in that protocol?

Yes. Holding the dose is a real option and it does not mean you have failed at anything.

the reimbursement criteria are published in most member states

Have you held a step for longer than the four-week minimum at any point?

the first fortnight after a step is the worst of it, then it settles

glycaemic control and weight are two different endpoints

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.